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Abstract
Arginase deficiency is a rare autosomal recessive disorder resulting from a loss of the liver arginase isoform, arginase 1
(ARG1), which is the final step in the urea cycle for detoxifying ammonia. ARG1 deficiency leads to hyperargininemia,
characterized by progressive neurological impairment, persistent growth retardation and infrequent episodes of
hyperammonemia. Using the Cre/loxP-directed conditional gene knockout system, we generated an inducible Arg1-
deficient mouse model by crossing ‘‘floxed’’ Arg1 mice with CreERT2 mice. The resulting mice (Arg-Cre) die about two weeks
after tamoxifen administration regardless of the starting age of inducing the knockout. These treated mice were nearly
devoid of Arg1 mRNA, protein and liver arginase activity, and exhibited symptoms of hyperammonemia. Plasma amino acid
analysis revealed pronounced hyperargininemia and significant alterations in amino acid and guanidino compound
metabolism, including increased citrulline and guanidinoacetic acid. Despite no alteration in ornithine levels, concentrations
of other amino acids such as proline and the branched-chain amino acids were reduced. In summary, we have generated
and characterized an inducible Arg1-deficient mouse model exhibiting several pathologic manifestations of hyperargini-
nemia. This model should prove useful for exploring potential treatment options of ARG1 deficiency.
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Introduction
The urea cycle disorders (UCDs) are a group of rare inborn
errors of hepatic metabolism causing malfunction in the nitrogen
clearance system. Deficiency in any of the enzymes in the urea
cycle results in perturbation of ureagenesis, thereby leading to
incomplete removal of ammonia from the blood stream and to
variable degrees of hyperammonemia. Arginase is the final
enzyme of the urea cycle and is of central importance in the
detoxification of ammonia in mammals. There are two isoforms of
arginase which are present at distinct intracellular sites: arginase 1
(ARG1) and arginase 2 (ARG2). ARG1, which is expressed
predominantly in the cytoplasm of the liver, hydrolyzes arginine
into ornithine and urea, where the latter is then excreted through
the kidneys in the urine [1,2]. In contrast, the second isoform,
mitochondrial ARG2 is distributed in extrahepatic tissues, such as
kidney and prostate, with lower levels in brain, gastrointestinal
tract and macrophages [2,3]. In patients with ARG1 deficiency
and hyperammonemic episodes, there is often a compensatory
increase in ARG2 activity in the kidney [4]. Although the exact
mechanism is not known, the augmented expression of ARG2 may
mitigate the phenotypic deterioration via residual ureagenesis
[1,4].
In humans, arginase deficiency generally refers to decreased
function of the liver arginase isoform, ARG1. This deficiency is
transmitted in an autosomal recessive manner and often leads to
hyperargininemia, a metabolic disorder characterized by progres-
sive neurological and intellectual impairment, spasticity and
persistent growth retardation [1]. Some patients may also display
intermittent episodes of behavior disturbance (irritability, hyper-
activity and aggression), feeding difficulties, vomiting, lethargy and
seizures [5]. Unlike other urea cycle disorders with early-onset
presentation, hyperargininemia usually presents after the neonatal
period, particularly between two to four years of age with
predominantly neurological manifestations and infrequent epi-
sodes of hyperammonemia. As ARG1-deficient patients rarely
develop hyperammonemia crises, they have a prolonged life span
compared to those with other urea cycle disorders. With early
intervention, some of the neurologic abnormalities can be partially
alleviated by low-protein diet, supplementation of essential amino
acids and administration of nitrogen-scavenging drugs, such as
sodium benzoate or sodium phenylbutyrate [1,6]. However, no
complete cure is currently available.
The ,12 kb gene for human liver arginase (ARG1) is located on
chromosome 6q23, composed of eight exons and seven introns
[7,8]. The genomic structure of ARG1 reveals a high level of
conservation with rodent Arg1 [8–10]. Mice with homozygous
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disruption of Arg1 were generated by Iyer and co-workers to study
the pathological mechanisms of the disease [11]. Their gene
knockout mouse model partially mimicked human conditions,
characterized by severe hyperammonemia and neurological
deterioration. However, unlike human subjects, which usually
survive into adulthood, these knockout mice died in the perinatal
period (between postnatal day 10–14). El Kasmi et al. [12]
developed macrophage-specific Arg1 knockout mice to circumvent
the neonatal mortality in order to study macrophage immune
functions of Arg1.
Here, using the Cre/loxP-directed conditional gene knockout
system [13], we report a new Arg1-deficient mouse model that
allows inducible temporal control of Arg1 deletion in mice.
Through tamoxifen-induced excision of floxed exons 7 and 8 of
Arg1 at four different age groups (neonatal, 4-, 8- and 12-weeks),
the resulting mice are shown to be nearly devoid of Arg1 activity.
Such deletion exhibited several pathobiochemical aspects of
hyperargininemia commonly seen in humans. We anticipate that
our model will yield novel insights into the roles of Arg1 and
address the development of potential gene therapeutic strategies
for the treatment of this disorder.
Materials and Methods
Generation of knockout mice
Arg1flox (JAX strain 008817, C57BL/6-Arg1tm1Pmu/J) [12] and
CreERT2 (JAX strain 008463, B6.129-Gt(ROSA)26Sortm1(cre/ERT2)-
Tyj/J) [14] mice were obtained from The Jackson Laboratory and
crossbred over two generations to obtain Arg1flox homozygous and
CreERT2 homozygous or heterozygous offspring. Newborns at
postnatal day 0 (P0) were intragastrically injected with 4-hydroxy-
tamoxifen (OHT) (Sigma) for two consecutive days, while mice at
4-, 8-, and 12- week of age received five consecutive intraperito-
neal injections of 1 mg tamoxifen (Sigma) [13] to induce excision
of exons 7 and 8 of the Arg1 gene. Control mice for side-by-side
comparison include Arg1flox mice which received equal volumes of
vehicle (5% ethanol in sunflower oil) (herein referred to as vehicle-
treated mice) and Cre mice which received equal volumes of
tamoxifen administration (herein referred to as ROSA mice).
Changes in body weight and dietary intake of mice were carefully
monitored daily during the experimental period. Food intake was
measured by pre-weighing food pellets and then constantly
weighing the remaining chow at the indicated times. All
procedures were reviewed and approved by the Queen’s
University Animal Care Committee (approval #Funk-2011-048-
R1-A4) and conformed to the Guidelines of the Canadian Council
on Animal Care. Unless otherwise specified, water and standard
rodent chow (protein 18.9%, fat 11%, fiber 2.2%, minerals 5.8%)
(5015 Mouse Diet, Lab Diet)) were provided ad libitum. In early
experiments, mice were treated with 1 ml of warmed Lactated
Ringer’s Solution (s.c.), which did not prove to be therapeutic. As
the study progressed, it became possible to predict 24 h before
mice would show signs of health deterioration and they were
euthanized by CO2 asphyxiation before exhibiting signs of distress.
Humane endpoints were defined as body weight loss of .15%
relative to the weight at the time of tamoxifen administration,
accompanied by hunched posture, lethargy and poor grooming.
Some mice could lose substantial weight in one day especially
when approaching the endpoint. For experimental consistency, all
mice were sacrificed 14 days after tamoxifen administration.
Approximately equal numbers of male and female mice were used
for all studies. Harvested tissues were flash-frozen in liquid
nitrogen and stored at 280uC prior to RNA isolation and
arginase activity assay.
PCR genotyping
Genomic DNA from ear punch or tail biopsy was extracted by
standard protocols and subjected to PCR for genotyping. Primer
sets for Arg1flox confirmation were as follows: 59- TGCGAGTT-
CATGACTAAGGTT-39 and reverse 59-AAAGCTCAGGT-
GAATCGG-39; for CreERT2: forward 59-AAAGTCGCTCT-
GAGTTGTTAT-39 and reverse 59-GGAGCGGGAGA-
AATGGATATG-39; and for Arg-Cre knockout: Arg1flox primer
set in combination with reverse primer 59-GCACTGTC-
TAAGCCCGAGAGTATC-39. The removal of exons 7 and 8
was confirmed four days following tamoxifen administration.
Cycle parameters: denaturation at 94uC for 30 sec, annealing at
64.5uC for 1 min, and elongation at 72uC for 1 min for 35 cycles.
Gait analysis
Gait characteristics were analyzed eight days after tamoxifen
administration by applying ink of different colors to the fore and
hind paws, and letting them walk on a folded paper ‘‘alley’’. The
footprint patterns were analyzed for four parameters (all measured
in centimeters): (i) stride length, as the average distance of forward
movement between each stride; (ii) forepaw base width and (iii)
hindpaw base width, as the average distance between left and right
forepaws, and left and right hindpaws, respectively by measuring
the perpendicular distance of a given footprint to a line connecting
its opposite preceding and proceeding footprints; and (iv) distance
from left or right forepaw/hindpaw overlap. Footprints made at
the beginning and end of the run were excluded.
Isolation of primary hepatocytes
Primary hepatocytes were isolated from mice using a modified
two-step collagenase perfusion system kept at 37uC [15]. Briefly,
mice were anesthetized with isoflurane and the portal vein was
cannulated. Upon successful cannulation, the inferior vena cava
(IVC) was immediately cut to allow fluid to drain. The liver was
perfused at a flow rate of 8–10 ml/min for 5 min with calcium-
and magnesium-free Hanks balanced salt solution. Digestion
buffer containing low glucose DMEM (Sigma) supplemented with
100 U/ml type IV collagenase (Worthington), 15 mM HEPES,
1.8 mM CaCl2 and 100 U/ml penicillin-streptomycin was then
perfused for an additional 10 min to digest the liver. Intermittent
clamping of the IVC was performed to augment total cell yield.
The liver was excised and cells were liberated by tearing and
shaking of the liver with forceps followed by gentle trituration. The
cell suspension was then filtered through a 70 mm strainer (BD
Biosciences), washed by centrifugation thrice (506 g for 3 min at
4uC) and resuspended in isolation medium [high glucose DMEM
(Sigma) supplemented with 15 mM HEPES (pH 7.4), 100 nM
dexamethasone, 10% FBS and 100 U/ml penicillin-streptomycin.
Cell viability was$90% as assessed by trypan blue exclusion. Cells
were plated on collagen-coated (5 mg/cm2 Type 1 rat collagen;
BD Biosciences) 6-well plates at 1 million cells per well. Cells were
allowed to attach for 45 min at 37uC in a humidified 5% CO2
incubator before changing the medium to low glucose DMEM
supplemented with 5 mM HEPES, 10 nM dexamethasone, 10%
FBS and 100 U/ml penicillin-streptomycin. After 4 hours of
attachment, the medium was replaced with serum-free low glucose
DMEM supplemented with 5 mM HEPES, 10 nM dexametha-
sone, 20 ng/ml epidermal growth factor (EGF), 10 mM nicotin-
amide and 100 U/ml penicillin-streptomycin for overnight
culture. Culture medium was changed daily. Medium was
collected and stored at 220uC for analysis of urea production.
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Real-time PCR for arginase-1 expression
Tissues were pulverized in liquid nitrogen prior to RNA
extraction. Total RNA was extracted with TRIzol reagent
(Invitrogen), followed by RNA cleanup using an RNeasy Kit
(Qiagen) as per the manufacturer’s instructions. cDNA was
synthesized from 1 mg of total RNA using an iScript cDNA
synthesis kit (Bio-Rad). Gene expression was determined by
quantitative PCR (Applied Biosystems Model 7500) using a
TaqMan Gene Expression Assay specific for Arg1 spanning exons
7 and 8 (Mm01190441_g1, Applied Biosystems) and Arg2
(Mm00477592_m1, Applied Biosystems). Mouse 18s rRNA Taq-
man primer-probe set (Mm03928990_gl, Applied Biosystems) was
used as internal reference for normalization. The reaction
mixtures prepared in duplicate each contained 206 TaqMan
mixture (Applied Biosystems), TaqMan primer-probe sets and 1 ml
of cDNA template in a total volume of 20 ml. Reaction conditions:
2 min at 50uC and 10 min at 95uC, followed by 40 cycles at 95uC
for 15 s and 60uC for 1 min. Relative gene expression was
calculated using the comparative threshold method (22DDCt) and is
presented as fold change of transcripts for Arg1 or Arg2 compared
to 18s rRNA.
Western blot analysis
Liver tissues were pulverized in liquid nitrogen and homoge-
nized in ice-cold RIPA buffer (Millipore) including protease
inhibitor cocktail (Roche). Twenty-micrograms of centrifuged,
clarified protein samples were subjected to Western blot analysis
and probed with rabbit polyclonal anti-Arg1 antibody (C-terminal)
(1:10000; Abcam, cat# ab91279) and mouse polyclonal anti-a-
tubulin antibody (1:5000, Sigma-Aldrich) used as loading control.
Immunoreactive proteins were detected using horseradish perox-
idase-conjugated goat anti-rabbit or anti-mouse secondary anti-
body (1:5000, Sigma-Aldrich) and visualized by enhanced
chemiluminescence detection (GE Healthcare).
Urea production assay
Urea produced by hepatocytes was measured colorimetrically
using a urea assay kit (Abnova) according to the manufacturer’s
instructions. Fresh culture media and known concentrations of
urea were used as negative and positive controls, respectively.
Urea reactions were performed in 96-well plates and concentra-
tions were assessed using a plate reader (FLUOstar OPTIMA,
BMG Labtech) at absorbance 520 nm.
Biochemical analysis of plasma
Whole blood samples were obtained from the saphenous or
submandibular vein prior to commencing the studies, as well as on
day 4, 7 and 11 following the final tamoxifen (or vehicle) injection.
Endpoint samples (on day 14 when the mice were sacrificed) were
obtained by post-mortem cardiac puncture. Briefly, plasma
collected in heparinized microhematocrit capillary tubes was
separated from red blood cells by centrifugation and assayed
immediately for ammonia concentration employing a commercial
kit (Sigma-Aldrich) using 10–20 ml of plasma for each sample
tested according to the manufacturer’s instructions. The absor-
bance was measured with a spectrophotometer (Varian Cary 50
Bio UV-visible spectrophotometer) at 340 nm. The ammonia
concentrations were calculated according to the non-competitive
reaction equation.
For the guanidino compound analysis, mouse plasma was
analyzed by HPLC cation-exchange chromatography using a
Beckman Coulter HPLC system (Fullerton, California, USA) with
post-column derivatization modified after Marescau et al. [16].
Plasma amino acids were analyzed by MassTrak Amino acid
Analysis Solution on an Acquity UPLC System (Waters, Milford
MA, USA). In brief, 5 ml of plasma sample was added to 10 ml of
5% albumin in saline solution to create a 36 dilution. Plasma
proteins were precipitated by adding 15 ml of 10% sulfosalicylic
acid solution containing the internal standard norvaline to the
15 ml of diluted plasma. Twenty microliters of derivatizing solution
was added to the mixture and then heated at 55uC for 10 minutes
prior to analysis.
Arginase activity assay
Arginase activities of all samples were assayed as described
previously [17]. Briefly, liver tissues were homogenized in a
solution containing 40 ml of 0.1% Triton X-100 and 16HALT
protease inhibitor cocktail per mg of tissue. Lysate (10 ml) was
diluted with water to a final volume of 100 ml, followed by the
addition of 100 ml of 25 mM Tris-HCl (pH 7.5) and 20 ml of
10 mM MnCl2. Arginase was activated by heating each sample at
56uC for 10 min. Samples were then added with 100 ml of 0.5 M
L-arginine (pH 7.9) as the substrate and incubated at 37uC for 1 h.
Arginase enzyme activity will cause L-arginine to convert to urea.
The conversion of arginine to urea was stopped by the addition of
900 ml of acid mixture [1:3:7 mixture of H2SO4 (96%):H3PO4
(85%):water]. Forty microliters of 9% solution of 1-phenyl-1,2-
propanedione-2-oxime (ISPF) dissolved in ethanol was then added
to each sample. The mixture was heated to 95uC for 30 min for
development of a purple color for urea. Each sample was diluted
1:6 with water and absorbance measured at 540 nm (Varian Cary
50 Bio UV-visible spectrophotometer). Urea standards ranging
from 0.03 to 0.5 mmol were used to create a standard curve for
each assay. The extent of arginase enzyme activity was normalized
to the protein content of each lysate, as measured by a Bradford
reagent assay using standard protocols.
Statistical analysis
Survival curves were computed in each group of mice using the
Kaplan-Meier method and compared across groups using the log
rank test. All results are expressed as mean 6 standard error of
mean (SEM). Statistical analysis was performed using GraphPad
Prism 6 (GraphPad Software, San Diego, California, USA). Means
were compared using the two-tailed Student’s t-test. P values of
,0.05 were considered statistically significant.
Results
Generation of an inducible Arg1 deficient mouse model
Using a conditional targeting strategy, we generated an
inducible Arg1-deficient mouse strain by crossing Arg1flox mice
[12] with mice expressing a ligand-dependent chimeric Cre
recombinase (CreERT2) (14). The ‘‘floxed’’ exons 7 and 8 of Arg1
were then deleted through Cre-mediated loxP recombination with
tamoxifen [13] to achieve nearly 100% penetrance of recombi-
nation. Three primers were used for genotyping four days after the
last tamoxifen/vehicle administration (for details see ‘Materials and
Methods’) (Fig. 1A) in 4 separate age groups of mice. As expected,
Arg1flox mice produced 1.2 kb and 252 bp bands (indicative of
intact exons 7 and 8). Successful excision of exons 7 and 8 of Arg1
yields a band of 195 bp characteristic of the Arg1D allele (Fig. 1B).
Verification of tamoxifen-induced inactivation of the Arg1
gene
Real-time qPCR analysis was carried out to determine whether
the deletion of exons 7 and 8 altered the transcriptional processing
of Arg1. Indeed, data show markedly reduced Arg1 transcripts,
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particularly in liver tissues of neonatal, 4-, 8- and 12-week
tamoxifen-treated Arg-Cre mice (Fig. 2A). In other tissues (brain,
kidney) where endogenous Arg1 expression in wildtype mice is
much lower than in liver, Arg1 mRNA also decreased but variably
in neonatal, 4- and 8-week tamoxifen-treated Arg-Cre mice.
However, there was no significant change in Arg1 expression in
brain and kidney in the 12-week group. In parallel, Western blots
were performed to assess the expression of Arg1 protein,
specifically in liver. As expected, immunoblotting results were in
accordance with real-time PCR data. While vehicle-treated
samples showed strong immunoreactive Arg1 bands, diminished
expression of hepatic Arg1 was observed in tamoxifen-treated mice
of all four age groups (Fig. 2B). Clearly, both qPCR and Western
blot analysis verified that Cre-mediated recombination occurred
after tamoxifen administration. In addition, measurement of renal
Arg2 mRNA levels was carried out to examine if its expression was
compensatorily modified in response to Arg1 ablation. Unlike
human ARG1-deficient patients with significant ARG2 induction
[4], our results showed no statistically significant changes in renal
Arg2 expression between the vehicle- and tamoxifen-treated Arg-
Cre mice (Fig. 2C).
Phenotypic characterization of inducible Arg1 deficient
mice
We next assessed the outcome of excision of Arg1 exons 7 and 8
on phenotypic presentation and survival. Vehicle- and tamoxifen-
Figure 1. Generation of inducible Arg1-deficient mice. (A) Experimental setup for the gene targeting strategy. Arg1flox mice were crossbred
with CreERT2 mice to generate Arg1-Cre mice. Four separate groups of mice have been tested for tamoxifen-mediated Cre removal of exons 7 and 8
of Arg1. The arrows depict the locations of primers used for genotyping the resulting mice with approximate sizes of the different PCR products
shown. (B) Representative agarose gel of PCR genotyping using genomic DNA from ear punch or tail biopsies of vehicle- and tamoxifen-treated Arg-
Cre mice. Arg1-Cre mice exhibited two bands at 1.2 kb and 252 bp, while knockout mice showed a single band at 195 bp.
doi:10.1371/journal.pone.0080001.g001
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treated Arg-Cre mice were grossly indistinguishable in phenotype
from each other until approximately day 10 following the final
tamoxifen injection. In tamoxifen-treated Arg-Cre mice, onset of
phenotypic disparities were typically heralded by ruffled coat, dull
eyes, and hunched body posture (Fig. 3A), followed by inactivity,
progressive signs of ataxia and respiratory distress over the next 3–
4 days. There were significant weight loss differences between the
groups during the study period, although all mice were provided a
standard chow diet ad libitum. In contrast to vehicle-treated mice,
which generally showed age-appropriate weight gain, rapid weight
loss was recorded in tamoxifen-treated mice starting at 7–10 days
after the final tamoxifen injection. Growth disparity was most
obvious in 4- and 8-week old mice, which exhibited up to 20% loss
of body weight relative to day 4 from the last tamoxifen/vehicle
injections, whereas ROSA mice exhibited little (in 8- and 12-week
old mice) or no weight loss (in 4-week old mice) (Fig. 3B). In the
last few days of life, when weight loss was progressing in
tamoxifen-treated 8-week old mice, chow feeding went from
baseline (5.460.5 g/day) to reduced (3.360.6 g/day) intake
(n = 3), while in vehicle-treated mice feeding stayed constant
(5.660.9 baseline vs 5.660.6 day 14 after last tamoxifen dose;
n = 3).
Kaplan-Meier survival curves of tamoxifen-treated mice vs
ROSA and vehicle-treated mice began to diverge on day 12 after
the last injection and remained apart until the end of the study
(Fig. 3C). In fact, the induced Arg1 deficient mice die about 2
weeks after tamoxifen administration, regardless of the starting age
for excision of exons. In addition, gait abnormalities were also
assessed quantitatively by analyzing the walking footprint patterns
of the mice (Fig. 3D). Vehicle-treated mice walked with a steady
alternating gait, whereas tamoxifen-treated mice adopted stagger-
ing movements showing irregularly spaced footprints. Although no
changes were observed in the forepaw base and hindpaw base
widths between the two groups, the tamoxifen-treated mice
displayed a significantly shorter stride length and a greater
distance between forepaw and hindpaw overlap, as compared
with vehicle-treated mice.
Effect of Arg-1 deficiency on liver functions
To biochemically characterize the inducible Arg1-deficient
mouse model, we performed arginase enzyme activity assays by
quantifying the amount of urea produced from liver lysates of
neonatal and adult mice aged between 4 to 12 weeks, treated with
either vehicle or tamoxifen. Arg1 enzyme activity was significantly
lower in the tamoxifen- treated group compared to the vehicle-
treated mice at the neonatal stage (58.063.1 vs 895616.6 nmoles
of urea/mg protein), 4 weeks of age (33.468.2 vs
418613.3 nmoles of urea/mg protein), 8 weeks of age (40.467.9
vs 476653.9 nmoles of urea/mg protein) and 12 weeks of age
(58.766.9 vs 537652.9 nmoles of urea/mg protein) (Fig. 4A). To
complement these studies, hepatic function was also assessed by
examining the ability of hepatocytes in vitro to synthesize urea.
Similar trends were observed in hepatocytes isolated from 4-, 8-
and 12-week tamoxifen-treated mice, showing a nearly 3- to 5-
fold reduction in urea production (Fig. 4B).
Figure 2. Down-regulation of Arg 1 expression in tamoxifen-treated Arg-Cre mice. (A) Transcriptional response of Arg1 to tamoxifen
induction. Real-time qPCR analysis of Arg 1 gene expression was performed in liver, brain and kidney tissues 12 days after tamoxifen administration.
Differences in RNA input for reverse transcription were normalized using Ct values obtained in parallel for mouse 18S rRNA. Fold change was
calculated relative to the vehicle-treated samples using the comparative threshold method (22DDCt). Values are mean 6 SEM for n= 3–6 in each
group. Statistical significance between groups was determined by Student’s t-test. *P,0.05, **P,0.01 and ***P,0.001. (B) Western blot analysis of
total liver extracts (20 mg/well) from four age groups. Arg1 protein expression was evaluated by immunoblotting with an anti-Arg1 antibody (C-
terminal) to confirm the level of knockdown. a-tubulin was used as loading control. Representative immunoblot from three independent experiments
is shown. (C) Real-time qPCR analysis of Arg 2 gene expression in kidney.
doi:10.1371/journal.pone.0080001.g002
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Biochemical abnormalities in plasma of tamoxifen-
treated Arg-Cre mice
Given that significant alterations in liver arginase activity and
urea synthesis were observed, further biochemical studies were
carried out. Plasma samples were collected from the three older
age groups of vehicle- or tamoxifen-treated Arg-Cre mice and
assayed for plasma ammonia concentration (PAC) at five different
time-points: baseline (before treatment), and at days 4, 7, 11 and
13–14 (humane endpoint) after the last vehicle or tamoxifen
injection. The percentage change in PAC in tamoxifen-treated vs
vehicle-treated mice was then analyzed for all time-points across
the three age groups (Fig. 5). The PAC for both the vehicle- and
tamoxifen-treated groups was similar at baseline. Also, no major
differences were evident at day 4 after the last injection. However,
at days 7, 11 and endpoint after the last injection, the percentage
change in PAC in tamoxifen-treated mice was significantly higher
compared to that at baseline, in 4-week old (38.5613.8; 40.166.0;
26366.4%, respectively), 8-week old (10.562.6; 27.3619.1;
18967.5%) and 12-week old mice (42.4613.2; 60.9611.7;
182615.9%, respectively).
Additionally, plasma amino acids and arginine metabolites of 4-
, 8- and 12-week old mice were measured at baseline and humane
endpoint. Compared to the vehicle-treated control mice, the levels
in plasma of several amino acids were significantly perturbed in
the tamoxifen-treated Arg-Cre mice (Table 1). Notably, the Arg1-
induced knockout mice exhibited hyperargininemia with arginine
levels nearly 8-fold greater than in ‘‘floxed’’ Arg1-Cre mice, which
incidentally were 1.6-fold higher than in Cre mice (data not
shown), presumably due to the loxP sites within the introns
partially affecting Arg1 expression. The induced Arg1 knockout
mice also showed an approximately 1.5–2.3-fold increase in
citrulline and guanidinoacetic acid (GAA), whereas proline was
reduced about 50% compared to the control vehicle-treated mice.
Whilst no significant differences were observed in glutamine,
Figure 3. Impact of inducible Arg1 knockout on phenotypic presentation. (A) Typical appearance of Arg1 knockout mouse at humane
endpoint (right), with healthy-appearing vehicle-treated control at the same timepoint (left). (B) Percent changes in body weight during the
experimental period relative to body weights taken four days following injections are shown on y-axis. (C) Kaplan-Meier survival curve comparison
depicts that tamoxifen-treated mice display significantly reduced survival rates when compared to ROSA and vehicle-treated mice. Data are mean 6
SEM for n = 5–11 in each group. Statistical significance between groups was determined by Student’s t-test (*P,0.05). (D) Quantitative analysis of
walking footprint patterns based on measurements of stride length, forepaw base and hindpaw base width, and distance between front and hind
footprint placement. (n = 6).
doi:10.1371/journal.pone.0080001.g003
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aromatic amino acids and acidic amino acids, alanine, asparagine,
glycine, methionine, serine, threonine, isoleucine, leucine and
valine were all reduced (about 25–50%) in the induced Arg1
knockout mice. The plasma level of ornithine, the product of Arg1
activity along with urea, however, was not significantly affected.
Discussion
Our understanding of the pathophysiologic processes underly-
ing Arg-1 deficiency can be greatly enhanced by the development
of appropriate knockout animal models. The first Arg1 knockout
mouse model was generated in 2002 by Iyer and coworkers by
replacing the active site of the Arg1 gene (exon 4) with a neomycin
resistance cassette [11]. However, the mice died before weaning
and were not amenable to further studies on somatic growth and
neurological development. To overcome these limitations, we
developed a novel time-dependent control of in vivo Arg1 gene
disruption using a tamoxifen-inducible Cre/loxP conditional
knockout strategy. Arg1 knockout mice spanning the neonatal
period to early adulthood were generated and demonstrated
significant deficits of Arg1 mRNA and protein expression in
various tissues with the effect most pronounced in liver where Arg1
expression was reduced to barely detectable levels. The unchanged
level of Arg1 mRNA level in the brain and kidney tissues of the 12-
week old tamoxifen-treated mice may be due to variable efficacy of
tamoxifen to reach estrogen receptor targets in these tissues in
older mice to induce Cre-mediated excision or to altered
chromatin structure at the Arg1 locus in these tissues that affects
excision efficiency.
Tamoxifen-treated Arg1-deficient mice exhibited progressive
weight loss and a neurological phenotype consistent with overt loss
of motor function with some aspects similar to human ARG1
deficiency [18]. Since the neuromotor deficits were observed
before severe weight loss, the lack of uniformity of step alternation
in Arg1-deficient mice is likely a consequence of Arg1 gene
disruption rather than changes in body weight. Nevertheless, more
specific tests at different time points would allow further appraisal
of this presumption. However, in contrast to human patients who
can often survive longterm, these mice died invariably by two
weeks after the last tamoxifen injection. Tamoxifen has been
associated with several side effects including weight loss due to its
direct toxic effect on gastric mucosa, thereby interfering with the
normal digestive processes [19]. Such effects are likely to cause
under nutrition with a consequent deleterious effect on body
weight and growth. To examine the effect of tamoxifen, ROSA
mice (that express the Cre transgene but do not possess floxed Arg1
alleles) treated with tamoxifen were also included in our early
experiments. These mice showed only a minor decrement in
weight loss (about 5% in 8- and 12-week old mice and no change
in 4-week old mice). Most importantly, this minimal degree of
weight loss did not affect survival rate, hence, excluding major
toxicity of tamoxifen in our studies.
Symptoms developed in ARG1-deficiency human patients are
generally less severe compared to other urea cycle disorders. The
overexpression of ARG2 is a potential compensatory response,
which can attenuate disease progression [1,4]. However, we found
no statistically significant evidence for renal Arg2 compensation in
our inducible Arg1 knockout mice resulting in a severe manifes-
tation of disease in mice compared to humans. Nevertheless, the
mice generated in our studies have proven highly useful for proof-
of-concept studies by exhibiting several hallmark presentations of
Arg-1 deficiency such as impaired hepatic arginase activity and
hyperargininemia.
Various degrees of metabolic derangements were caused by the
inducible knockout of Arg1 activity. The level of free ammonia in
plasma was significantly increased in Arg1-deficient mice, but
glutamine which functions as temporary ‘repository’ for ammonia
was not significantly affected. The accumulation of ammonia is a
deleterious consequence of impaired ureagenesis and leads to
toxicity in the central nervous system (CNS). Interestingly, other
amino acids such as alanine, asparagine, glycine, methionine,
proline, serine and threonine, which play roles in the incorpora-
tion of ammonia nitrogen were all significantly reduced. These
observations are paradoxical, suggesting an alternative ammonia-
Figure 4. Reduced arginase enzyme activity and urea production in tamoxifen-treated Arg-Cre mice. (A) Arginase activity in liver tissue
extracts from vehicle- and tamoxifen-treated mice. The livers were homogenized and the arginase enzyme activity assay was carried out as
mentioned in the ‘‘Materials and Methods’’ section. (B) Functional capacity of hepatocytes assessed by determining urea production. Isolation of
primary mouse hepatocytes was performed based on the two-step collagenase perfusion technique. Typical morphology of mouse hepatocytes
cultured on a single layer of collagen gel at 24 h (top panel). Hepatocyte urea production was spectrophotometrically determined at 544 nm (bottom
panel). Values are mean 6 SEM for n = 3–7 in each group. *P,0.05, **P,0.01 and ***P,0.001.
doi:10.1371/journal.pone.0080001.g004
Figure 5. Tamoxifen-mediated inducible Arg1 knockout leads to hyperammonemic crisis. Plasma ammonia assay performed at five
different time-points of three age groups. Values are expressed as percentage change in plasma ammonia concentration in tamoxifen-treated mice
compared to vehicle-treated control mice. Ammonia concentrations ranged between 305–595 mmol/L (vehicle-treated mice) and 903–1791 mmol/L
(tamoxifen-treated mice). Data are mean 6 SEM for n= 3–5 in each group. *P,0.05, **P,0.01 and ***P,0.001.
doi:10.1371/journal.pone.0080001.g005
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scavenging pathway may be involved. In addition to hyperam-
monemia, profound hyperargininemia was present in tamoxifen-
treated mice accompanied by modestly elevated guanidinoacetic
acid (GAA) and the liver urea cycle intermediate citrulline. The
guanidino group of arginine is required to yield guanidinoacetic
acid (GAA), and subsequently creatine and creatinine via the
transaminidation pathway. Clearly, ammonia is not solely
responsible for the neurologic insult in these mice. In fact, elevated
arginine and guanidino compounds may also result in neurotox-
icity via augmented nitric oxide synthesis, thereby leading to
oxidative damage to the brain [20]. Indeed, several guanidino
compounds were previously shown to be increased in plasma,
cerebrospinal fluid (CSF), as well as brain tissue of hyperargini-
nemic patients [21,22] and in the mouse model [23].
Another finding of this study is a significant 50% reduction of
plasma proline concentration in Arg1-deficient mice. Proline has
the potential to suppress reactive oxygen species (ROS) and could
contribute to aberrant redox homeostasis [24]. Due to its
neuroprotective role, plasma proline is a promising biomarker of
neurological deficits [25]. Taken together, the deficit in coordi-
nated neuromotor abilities observed in inducible Arg-1 deficient
mice is likely resulting from a combinatorial effect of hyperam-
monemia, accumulation of arginine and its metabolites, such as
guanidino compounds, as well as alterations of other amino acids.
Additional studies will be required to elucidate the mechanisms of
cognitive impairment in the brain. Elevated arginine and
ammonia concentrations have been reported to be associated
with reduced concentrations of branched-chain amino acids
(BCAA) such as isoleucine, leucine and valine [26,27], which is
in line with our observations. Hyperargininemia and hyperam-
monemia promote BCAA degradation and catabolism, respec-
tively, for lean tissue growth by enhancing mitochondrial oxidative
function in skeletal muscle. Further investigations examining
whole-body composition, as well as energy expenditure in the
control and inducible Arg1-deficient mice could reveal clues to the
mechanisms for the observed phenotypes.
Notably, the abnormalities in most amino acid levels seen in our
tamoxifen-treated mice coincided with the growth retardation
phase that they incurred about 10 days following tamoxifen
administration. These mice demonstrated failure to thrive,
followed by rapid weight loss and early mortality. There are a
few possibilities for this observation. First, an adaptive homeostatic
mechanism may be initiated in response to changes in amino acid
concentration in the body. When the capacity to degrade excess
amino acids is impaired, a mechanism for modification of feeding
behavior will come into play. According to the aminostatic
hypothesis, an imbalance of plasma amino acids may trigger
satiety signals in the brain, thereby affecting food consumption
[28]. It was later demonstrated that increased plasma amino acids
results in a waning of appetite, suggesting an implication of an
appetite-controlling mechanism [29], which is initiated by the
hypothalamic neuronal circuitry [30]. In fact, there is a reciprocal
causal relationship between plasma amino acid concentrations and
appetite, where hunger is suppressed as amino acid levels rises. In
this context, there is a possibility that the tremendous rise of
arginine in our Arg1-deficient mice has initiated a signal to reduce
food intake that leads to subsequent body weight loss. Prolonged
low level of food intake likely affects amino acid homeostasis, as
reflected in the altered plasma amino acids, which may eventually
be fatal for the induced knockout mice. A second explanation
Table 1. Plasma amino acid analysis of mice from different age groups (pooled) measured at humane endpoint.
Vehicle-treated mice Tamoxifen-treated mice P value
BCAA Valine 204617.5 12468.0 ,0.001
Isoleucine 71.764.0 51.964.1 ,0.01
Leucine 146613.4 98.067.3 ,0.01
Aromatic Phenylalanine 108613.2 90.764.2 NS
Tryptophan 94.6611.3 83.767.9 NS
Tyrosine 79.2611.3 55.363.7 NS
Heterocyclic Proline 99.167.3 52.662.0 ,0.001
Carboxamide Asparagine 56.169.4 30.361.2 ,0.05
Glutamine 700638.8 684629.7 NS
Hydroxy Serine 147613.9 81.863.5 ,0.001
Threonine 188613.1 89.063.6 ,0.001
Monoamino, monocarboxylic Alanine 451637.3 211619.0 ,0.001
Glycine 244618.7 13866.7 ,0.001
Diamino, monocarboxylic Histidine 97.6614.3 72.564.4 NS
Lysine 318631.1 342641.5 NS
Monoamino, dicarboxylic Aspartic acid 19.661.6 17.962.0 NS
Glutamic acid 54.966.0 44.465.4 NS
Urea cycle-related Arginine 10067.9 784662.1 ,0.001
Citrulline 61.462.7 89.764.5 ,0.001
Ornithine 78.767.5 70.0620.5 NS
Thioether Methionine 81.268.1 43.063.7 ,0.001
Guanidino compound Guanidino acetic acid 1.260.1 2.860.3 ,0.001
Values are mean 6 SEM for n = 11–12 and are expressed as micromoles per liter (mmol/L). BCAA, branched chain amino acid; NS, not significant.
doi:10.1371/journal.pone.0080001.t001
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involves an anorexigenic effect (appetite-suppressing) due to
marked elevation in plasma ammonia. Ammonium ion serves as
a regulator of insulin secretion where the latter is a potent
anorexigenic hormone [31]. The Arg1 deficiency-elicited rise in
plasma ammonia could indirectly reshape feeding patterns
through the effect of insulin. More importantly, ammonia is
mainly produced in the gut before transport to the liver for
detoxification. At this time, we are uncertain whether body weight
loss is the main precipitating cause of death in the tamoxifen-
treated Arg1 knockout mice or if it is due to ammonia elevation, or
a combination of both factors.
Conceivably, the plasma ornithine concentration should also
decrease as a result of reduced flux through Arg1. The results from
the present study however, show that ornithine was not
significantly altered in our knockout mice, arguing against Arg1
in the regulation of ornithine production. This was an unexpected
finding and is in contrast to the original Arg1 knockout model,
which exhibited hypoornithinemia [11]. There is a potential
explanation in that the ornithine aminotransferase reaction
converts ornithine to L-1-pyrroline-5-carboxylate (5PC), an
intermediate of proline synthesis. In humans, this reaction is
almost irreversible, except in the neonatal period, towards 5PC
formation, but in mice it could be possible that there is a reverse
flux that leads to ornithine formation by consuming proline. This
would explain both the low proline and normal ornithine levels.
Many of the symptoms found in human ARG1-deficiency can be
partially alleviated through ornithine supplementation. However,
our attempts to ameliorate the biochemical consequences of Arg1
deficiency with ornithine in the drinking water were unsuccessful,
despite markedly increased ornithine levels (data not shown). From
these observations, it is postulated that arginase inactivity may be
compensated by other unknown mechanisms regulating plasma
ornithine levels.
After we had written this manuscript, Kasten et al. [32]
reported a similar mouse model using a different tamoxifen
regimen (single oral dose of about 4 mg vs five6 1 mg daily i.p.
doses in 4-, 8-, 12- week old mice or two intragastric
administrations in neonatal mice in our studies), which resulted
in inconsistent recombination and variable loss of Arg1 activity in
[32] vs virtually complete knockout of Arg1 in our studies in all
mice. Humane endpoints differed substantially (.30% loss of body
weight [32] vs .15% here). Therefore, survival was gauged as
longer in [32] at 21.5 days vs 19 days (as counted from the first day
of tamoxifen administration or 14 days from the last day) in our
studies. There were some differences in plasma amino acids and
ornithine levels that may be partially associated with the different
blood sampling methods used [33]. In contrast to the retro-orbital
plexus bleeding technique employed in [32], we collected blood
via the submandibular facial vein, which required only momentary
restraint without the need for anesthesia, thereby eliminating
potential drug effects on metabolic parameters and allowed for
repeated blood sampling at multiple time points particularly to
monitor the changes in plasma ammonia.
In conclusion, we present here a novel animal model for
studying Arg1-deficiency at any time point during the normal
lifespan of a mouse. The inducible Arg1 knockout mice displayed a
unique biochemical phenotype. Titration of the extent of Arg1
gene disruption by modulating the typical tamoxifen administra-
tion regimen [13] may yield mice that survive much longer and
display typical neurological characteristics observed in human
ARG1 deficiency. Additionally, gene therapeutic approaches
similar or distinct from those tested recently [17,34,35] can be
attempted and will allow for the study of the exciting roles for Arg1
in immune function, as well as in the pathophysiology of
cardiovascular disease, asthma and cancer.
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